- Home
- TDS vs APGE Comparison
TDS vs APGE Comparison
Compare TDS & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDS | APGE |
|---|---|---|
| Founded | 1968 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | TDS | APGE |
|---|---|---|
| Price | $43.95 | $84.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $53.33 | ★ $109.67 |
| AVG Volume (30 Days) | 649.7K | ★ 1.1M |
| Earning Date | 05-01-2026 | 03-02-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.07 | $26.20 |
| 52 Week High | $47.80 | $85.04 |
Technical Indicators
Market Signals| Indicator | TDS | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 64.04 |
| Support Level | $43.02 | $73.06 |
| Resistance Level | $45.02 | N/A |
| Average True Range (ATR) | 1.27 | 4.70 |
| MACD | 0.07 | 1.27 |
| Stochastic Oscillator | 95.89 | 90.93 |
Price Performance
Historical ComparisonAbout TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.